These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30911578)

  • 1. Randomized, double-blind, placebo-controlled study of interferon-
    Lynch DR; Hauser L; McCormick A; Wells M; Dong YN; McCormack S; Schadt K; Perlman S; Subramony SH; Mathews KD; Brocht A; Ball J; Perdok R; Grahn A; Vescio T; Sherman JW; Farmer JM
    Ann Clin Transl Neurol; 2019 Mar; 6(3):546-553. PubMed ID: 30911578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label pilot study of interferon gamma-1b in Friedreich ataxia.
    Seyer L; Greeley N; Foerster D; Strawser C; Gelbard S; Dong Y; Schadt K; Cotticelli MG; Brocht A; Farmer J; Wilson RB; Lynch DR
    Acta Neurol Scand; 2015 Jul; 132(1):7-15. PubMed ID: 25335475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IFN-γ for Friedreich ataxia: present evidence.
    Wells M; Seyer L; Schadt K; Lynch DR
    Neurodegener Dis Manag; 2015 Dec; 5(6):497-504. PubMed ID: 26634868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients.
    Marcotulli C; Fortuni S; Arcuri G; Tomassini B; Leonardi L; Pierelli F; Testi R; Casali C
    Neurol Sci; 2016 Mar; 37(3):361-4. PubMed ID: 26621361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.
    Yiu EM; Tai G; Peverill RE; Lee KJ; Croft KD; Mori TA; Scheiber-Mojdehkar B; Sturm B; Praschberger M; Vogel AP; Rance G; Stephenson SE; Sarsero JP; Stockley C; Lee CY; Churchyard A; Evans-Galea MV; Ryan MM; Lockhart PJ; Corben LA; Delatycki MB
    J Neurol; 2015 May; 262(5):1344-53. PubMed ID: 25845763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial.
    Mariotti C; Fancellu R; Caldarazzo S; Nanetti L; Di Bella D; Plumari M; Lauria G; Cappellini MD; Duca L; Solari A; Taroni F
    Mov Disord; 2012 Mar; 27(3):446-9. PubMed ID: 22411849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.
    Lynch DR; Willi SM; Wilson RB; Cotticelli MG; Brigatti KW; Deutsch EC; Kucheruk O; Shrader W; Rioux P; Miller G; Hawi A; Sciascia T
    Mov Disord; 2012 Jul; 27(8):1026-33. PubMed ID: 22744651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia--a dose-response trial.
    Nachbauer W; Hering S; Seifert M; Steinkellner H; Sturm B; Scheiber-Mojdehkar B; Reindl M; Strasak A; Poewe W; Weiss G; Boesch S
    Cerebellum; 2011 Dec; 10(4):763-9. PubMed ID: 21597884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin in Friedreich ataxia.
    Mariotti C; Nachbauer W; Panzeri M; Poewe W; Taroni F; Boesch S
    J Neurochem; 2013 Aug; 126 Suppl 1():80-7. PubMed ID: 23859343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia.
    Boesch S; Nachbauer W; Mariotti C; Sacca F; Filla A; Klockgether T; Klopstock T; Schöls L; Jacobi H; Büchner B; vom Hagen JM; Nanetti L; Manicom K
    Mov Disord; 2014 Jun; 29(7):935-9. PubMed ID: 24515352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia.
    Saccà F; Puorro G; Marsili A; Antenora A; Pane C; Casali C; Marcotulli C; Defazio G; Liuzzi D; Tatillo C; Cambriglia DM; Schiano di Cola G; Giuliani L; Guardasole V; Salzano A; Ruvolo A; De Rosa A; Cittadini A; De Michele G; Filla A
    Mov Disord; 2016 May; 31(5):734-41. PubMed ID: 26879839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.
    Lynch DR; Perlman SL; Meier T
    Arch Neurol; 2010 Aug; 67(8):941-7. PubMed ID: 20697044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe Study).
    Lynch DR; Chin MP; Delatycki MB; Subramony SH; Corti M; Hoyle JC; Boesch S; Nachbauer W; Mariotti C; Mathews KD; Giunti P; Wilmot G; Zesiewicz T; Perlman S; Goldsberry A; O'Grady M; Meyer CJ
    Ann Neurol; 2021 Feb; 89(2):212-225. PubMed ID: 33068037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Omaveloxolone in Friedreich's Ataxia: Delayed-Start Analysis of the MOXIe Extension.
    Lynch DR; Chin MP; Boesch S; Delatycki MB; Giunti P; Goldsberry A; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; O'Grady M; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Meyer CJ
    Mov Disord; 2023 Feb; 38(2):313-320. PubMed ID: 36444905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol Treatment Is Safe and Increases Frataxin Levels in Friedreich Ataxia Patients.
    Alemany-Perna B; Tamarit J; Cabiscol E; Delaspre F; Miguela A; Huertas-Pons JM; Quiroga-Varela A; Merchan Ruiz M; López Domínguez D; Ramió I Torrentà L; Genís D; Ros J
    Mov Disord; 2024 Jul; 39(7):1099-1108. PubMed ID: 38696306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia.
    Nachbauer W; Wanschitz J; Steinkellner H; Eigentler A; Sturm B; Hufler K; Scheiber-Mojdehkar B; Poewe W; Reindl M; Boesch S
    Mov Disord; 2011 Aug; 26(10):1935-8. PubMed ID: 21692115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin.
    Boesch S; Sturm B; Hering S; Goldenberg H; Poewe W; Scheiber-Mojdehkar B
    Ann Neurol; 2007 Nov; 62(5):521-4. PubMed ID: 17702040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.
    Elincx-Benizri S; Glik A; Merkel D; Arad M; Freimark D; Kozlova E; Cabantchik I; Hassin-Baer S
    J Child Neurol; 2016 Jul; 31(8):1036-40. PubMed ID: 27029487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data.
    Lynch DR; Goldsberry A; Rummey C; Farmer J; Boesch S; Delatycki MB; Giunti P; Hoyle JC; Mariotti C; Mathews KD; Nachbauer W; Perlman S; Subramony SH; Wilmot G; Zesiewicz T; Weissfeld L; Meyer C
    Ann Clin Transl Neurol; 2024 Jan; 11(1):4-16. PubMed ID: 37691319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.